Roivant announced a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris, a highly morbid inflammatory scalp disorder affecting approximately 100,000 adults in the United States.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Bernstein bullish on Roivant Sciences, initiates with an Outperform
- Roivant Sciences initiated with an Outperform at Bernstein
- Roivant Sciences price target raised to $33 from $31 at JPMorgan
- Midday Fly By: Stocks climb as oil prices pull back
- Video: Moderna advances as settlement seen removing share overhang